Insulet Corporation (PODD) Stock Analysis

Insulet Corporation makes wearable, tubeless insulin pumps for people living with insulin-dependent diabetes. Based in Acton, Massachusetts, the medical device company sells its flagship Omnipod platform—including the automated Omnipod 5 and Omnipod DASH systems—directly to patients through retail pharmacies and independent distributors. The devices use Bluetooth to talk directly to continuous glucose monitors, automatically adjusting insulin delivery without daily injections or tangled tubes. Insulet also manufactures drug-delivery pods for Amgen’s Neulasta Onpro chemotherapy kits, giving it a steady secondary revenue stream outside diabetes care.

Insulet dominates the tubeless pump category, giving it a clear competitive moat over traditional tubed-pump rivals like Medtronic and Tandem Diabetes Care. Its disposable, patch-style design makes switching from daily needle injections far less intimidating for new patients than committing to a bulky, wired device. The pharmacy distribution model is another massive advantage, letting patients pick up pods like a regular prescription rather than navigating slow medical equipment channels. The primary risk is competition from rival closed-loop systems and retaining newly diagnosed Type 2 patients who drop off early in treatment.

Business is expanding rapidly, with Insulet posting $801.7 million in revenue for the second quarter of 2026, a 23.5% jump year-over-year. International sales are driving heavy momentum with 35.5% quarterly growth, proving that global demand for automated insulin delivery is still largely untapped. Management trimmed full-year U.S. Omnipod growth expectations to 17% to 19% after seeing higher-than-expected patient dropouts in the first 90 days of Type 2 adoption. Even with that near-term friction, Insulet is firmly on offense, investing in customer onboarding while preparing its next-generation Omnipod 6 rollout for 2027.